Vanda Pharmaceuticals Reports Q4 & FY25 Results, NEREUS Approval, and Bysanti PDUFA Date

summarizeSummary

Vanda Pharmaceuticals reported a significant net loss for Q4 and full year 2025, impacted by a large non-cash tax charge and cash burn, but announced FDA approval for NEREUS and provided 2026 revenue guidance.

check_boxKey Events

• Full Year 2025 Financial Results

  Vanda reported total revenues of $216.1 million, a 9% increase from 2024. However, the company posted a net loss of $220.5 million, significantly impacted by a $113.7 million non-cash deferred tax asset valuation allowance. Cash, cash equivalents, and marketable securities decreased by $110.8 million year-over-year to $263.8 million.

• NEREUS (tradipitant) FDA Approval

  The FDA approved NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking the first new oral therapy for this condition in over 40 years. The company plans a commercial launch and a Phase III program for its use in preventing vomiting from GLP-1 analogs.

• Bysanti (milsaperidone) NDA Under Review

  The New Drug Application (NDA) for Bysanti (milsaperidone) for bipolar I disorder and schizophrenia is currently under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2026.

• 2026 Revenue Guidance Provided

  Vanda provided 2026 financial guidance for its currently commercialized products (Fanapt, HETLIOZ, and PONVORY), projecting total revenues between $230 million and $260 million, indicating expected growth from these products.

auto_awesomeAnalysis

Vanda Pharmaceuticals reported a substantial net loss for the full year 2025, primarily driven by a significant non-cash deferred tax asset valuation allowance. The company also experienced a notable decrease in its cash position. However, these financial challenges are partially offset by strong operational and regulatory advancements, including the FDA approval of NEREUS for motion-induced vomiting, which represents a new commercial product. Additionally, the New Drug Application for Bysanti is under FDA review with a near-term PDUFA date, and the company submitted a Biologics License Application for imsidolimab. The 2026 revenue guidance for existing products indicates expected growth. This mixed report highlights financial pressures alongside promising pipeline progress, following the recent rejection of the HETLIOZ sNDA for jet lag disorder.